About Us Services Careers FAQ Contact Us 0
Home Healthcare IT Multiple Sclerosis Market Size, Share & Growth Report | By 2032
Multiple Sclerosis Market

Multiple Sclerosis Market Size, Share & Trends Analysis Report By Drug Type (Immunomodulatory, Immunosuppressant, Interferons, Corticosteroids), By Route of Administration (Oral, Parenteral) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2024-2032

Report Code: SRHI929DR
Last Updated : December 10, 2024
Author : Straits Research
Starting From
USD 2300
Buy Now
File Formats

Table Of Content

  1. Executive Summary
    1. Research Objectives
    2. Limitations & Assumptions
    3. Market Scope & Segmentation
    4. Currency & Pricing Considered
    1. Emerging Regions / Countries
    2. Emerging Companies
    3. Emerging Applications / End Use
    1. Drivers
    2. Market Warning Factors
    3. Latest Macro Economic Indicators
    4. Geopolitical Impact
    5. Technology Factors
    1. Porters Five Forces Analysis
    2. Value Chain Analysis
    1. North America
    2. Europe
    3. APAC
    4. Middle East and Africa
    5. LATAM
  2. ESG Trends
    1. Global Multiple Sclerosis Market Introduction
    2. By Drug Type
      1. Introduction
        1. Drug Type By Value
      2. Immunomodulatory
        1. By Value
      3. Immunosuppressant
        1. By Value
      4. Interferons
        1. By Value
      5. Corticosteroids
        1. By Value
    3. By Route of Administration
      1. Introduction
        1. Route of Administration By Value
      2. Oral
        1. By Value
      3. Parenteral
        1. By Value
    1. Introduction
    2. By Drug Type
      1. Introduction
        1. Drug Type By Value
      2. Immunomodulatory
        1. By Value
      3. Immunosuppressant
        1. By Value
      4. Interferons
        1. By Value
      5. Corticosteroids
        1. By Value
    3. By Route of Administration
      1. Introduction
        1. Route of Administration By Value
      2. Oral
        1. By Value
      3. Parenteral
        1. By Value
    4. U.S.
      1. By Drug Type
        1. Introduction
          1. Drug Type By Value
        2. Immunomodulatory
          1. By Value
        3. Immunosuppressant
          1. By Value
        4. Interferons
          1. By Value
        5. Corticosteroids
          1. By Value
      2. By Route of Administration
        1. Introduction
          1. Route of Administration By Value
        2. Oral
          1. By Value
        3. Parenteral
          1. By Value
    5. Canada
    1. Introduction
    2. By Drug Type
      1. Introduction
        1. Drug Type By Value
      2. Immunomodulatory
        1. By Value
      3. Immunosuppressant
        1. By Value
      4. Interferons
        1. By Value
      5. Corticosteroids
        1. By Value
    3. By Route of Administration
      1. Introduction
        1. Route of Administration By Value
      2. Oral
        1. By Value
      3. Parenteral
        1. By Value
    4. U.K.
      1. By Drug Type
        1. Introduction
          1. Drug Type By Value
        2. Immunomodulatory
          1. By Value
        3. Immunosuppressant
          1. By Value
        4. Interferons
          1. By Value
        5. Corticosteroids
          1. By Value
      2. By Route of Administration
        1. Introduction
          1. Route of Administration By Value
        2. Oral
          1. By Value
        3. Parenteral
          1. By Value
    5. Germany
    6. France
    7. Spain
    8. Italy
    9. Russia
    10. Nordic
    11. Benelux
    12. Rest of Europe
    1. Introduction
    2. By Drug Type
      1. Introduction
        1. Drug Type By Value
      2. Immunomodulatory
        1. By Value
      3. Immunosuppressant
        1. By Value
      4. Interferons
        1. By Value
      5. Corticosteroids
        1. By Value
    3. By Route of Administration
      1. Introduction
        1. Route of Administration By Value
      2. Oral
        1. By Value
      3. Parenteral
        1. By Value
    4. China
      1. By Drug Type
        1. Introduction
          1. Drug Type By Value
        2. Immunomodulatory
          1. By Value
        3. Immunosuppressant
          1. By Value
        4. Interferons
          1. By Value
        5. Corticosteroids
          1. By Value
      2. By Route of Administration
        1. Introduction
          1. Route of Administration By Value
        2. Oral
          1. By Value
        3. Parenteral
          1. By Value
    5. Korea
    6. Japan
    7. India
    8. Australia
    9. Singapore
    10. Taiwan
    11. South East Asia
    12. Rest of Asia-Pacific
    1. Introduction
    2. By Drug Type
      1. Introduction
        1. Drug Type By Value
      2. Immunomodulatory
        1. By Value
      3. Immunosuppressant
        1. By Value
      4. Interferons
        1. By Value
      5. Corticosteroids
        1. By Value
    3. By Route of Administration
      1. Introduction
        1. Route of Administration By Value
      2. Oral
        1. By Value
      3. Parenteral
        1. By Value
    4. UAE
      1. By Drug Type
        1. Introduction
          1. Drug Type By Value
        2. Immunomodulatory
          1. By Value
        3. Immunosuppressant
          1. By Value
        4. Interferons
          1. By Value
        5. Corticosteroids
          1. By Value
      2. By Route of Administration
        1. Introduction
          1. Route of Administration By Value
        2. Oral
          1. By Value
        3. Parenteral
          1. By Value
    5. Turkey
    6. Saudi Arabia
    7. South Africa
    8. Egypt
    9. Nigeria
    10. Rest of MEA
    1. Introduction
    2. By Drug Type
      1. Introduction
        1. Drug Type By Value
      2. Immunomodulatory
        1. By Value
      3. Immunosuppressant
        1. By Value
      4. Interferons
        1. By Value
      5. Corticosteroids
        1. By Value
    3. By Route of Administration
      1. Introduction
        1. Route of Administration By Value
      2. Oral
        1. By Value
      3. Parenteral
        1. By Value
    4. Brazil
      1. By Drug Type
        1. Introduction
          1. Drug Type By Value
        2. Immunomodulatory
          1. By Value
        3. Immunosuppressant
          1. By Value
        4. Interferons
          1. By Value
        5. Corticosteroids
          1. By Value
      2. By Route of Administration
        1. Introduction
          1. Route of Administration By Value
        2. Oral
          1. By Value
        3. Parenteral
          1. By Value
    5. Mexico
    6. Argentina
    7. Chile
    8. Colombia
    9. Rest of LATAM
    1. Multiple Sclerosis Market Share By Players
    2. M&A Agreements & Collaboration Analysis
    1. Biogen Inc.
      1. Overview
      2. Business Information
      3. Revenue
      4. ASP
      5. SWOT Analysis
      6. Recent Developments
    2. Sanofi
    3. GlaxoSmithKline plc.
    4. Celgene Corporation
    5. Pfizer Inc. 
    6. Novartis AG
    7. Teva Pharmaceuticals
    8. Synthetic Biologics Inc.
    9. Bayer AG
    10. Serono Inc.
    11. EMD Opexa Therapeutics Inc.
    12. Active Biotech AB
    13. Merck and Co.
    14. Actelion Pharmaceuticals Ltd.
    15. Innate Immunotherapeutics
    16. InnoBioscience LLC
    1. Research Data
      1. Secondary Data
        1. Major secondary sources
        2. Key data from secondary sources
      2. Primary Data
        1. Key data from primary sources
        2. Breakdown of primaries
      3. Secondary And Primary Research
        1. Key industry insights
    2. Market Size Estimation
      1. Bottom-Up Approach
      2. Top-Down Approach
      3. Market Projection
    3. Research Assumptions
      1. Assumptions
    4. Limitations
    5. Risk Assessment
    1. Discussion Guide
    2. Customization Options
    3. Related Reports
  3. Disclaimer

Related Reports

Global Report
The global multiple sclerosis drugs market size was valued at USD 24.54 billion in 2022. It is projected to reach USD 34.03 billion by 2031, growing with a CAGR of 3.7% during the forecast period (2023–2031). Multiple sclerosis (MS) is a chron
Buy Now

Purchase Benefits

  • Eligible for a free updated report next year
  • Completely customizable scope
  • 30% discount on your next purchase
  • Dedicated account manager
  • Query resolution within 24 hours
  • Permission to print the report

We are featured on :

www.straitsresearch.com
© Copyright 2025. All rights Reserved.